Interview with Dr. William Carter, CEO of Hemispherx Biopharma |
 |
 |
| By M.E.Garza | |
| Friday, 09 October 2009 03:00 | |
|
During the interview, there are references made to various materials which can be found/downloaded/seen via the links on the right.
Disclosure: No Positions
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application.
about 1 hour ago
A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY
about 2 hours ago
$JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 3 hours ago
$PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 4 hours ago
Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 5 hours ago
When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 6 hours ago
Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 6 hours ago
Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 9 hours ago
Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9
Free Phone Trade Alerts
